UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 24, 2012
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] |
No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Novo Nordisk A/S : Novo Nordisk A/S - Reduction of the share capital
At Novo Nordisk's Annual General Meeting on 21 March 2012, it was decided to reduce the company's B share capital from DKK 472,512,800 to DKK 452,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 20,000,000 B shares of DKK 1 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 20,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 560,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 452,512,800.
The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Company Announcement no 26 / 2012 |
Page 1 of 2 | |||
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR no: 24256790 |
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Further information: |
|
|
|
Media: |
Investors: |
|
|
Anne Margrethe Hauge |
Klaus Bülow Davidsen |
Tel: (+45) 4442 3450 |
Tel: (+45) 4442 3176 |
amhg@novonordisk.com |
klda@novonordisk.com |
|
|
|
Frank Daniel Mersebach |
|
Tel: (+45) 4442 0604 |
|
fdni@novonordisk.com |
|
|
|
Lars Borup Jacobsen |
|
Tel: (+45) 3075 3479 |
|
lbpj@novonordisk.com |
|
|
In North America: |
|
Ken Inchausti |
Jannick Lindegaard |
Tel: (+1) 609 514 8316 |
Tel: (+1) 609 786 4575 |
kiau@novonordisk.com |
jlis@novonordisk.com |
Company Announcement no 26 / 2012 |
Page 2 of 2 | |||
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR no: 24256790 |